Total Payments
$7,376
2024 Payments
$17.92
Companies
36
Transactions
431
Medicare Patients
7,621
Medicare Billing
$716,553
Payment Breakdown by Category
Food & Beverage$7,346 (99.6%)
Education$29.26 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,346 | 427 | 99.6% |
| Education | $29.26 | 4 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $703.31 | 46 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $699.26 | 55 | $0 (2021) |
| Amgen Inc. | $666.11 | 39 | $0 (2021) |
| Gilead Sciences, Inc. | $594.79 | 38 | $0 (2019) |
| Amarin Pharma Inc. | $577.59 | 29 | $0 (2021) |
| Abbott Laboratories | $534.66 | 16 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $493.76 | 22 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $457.08 | 33 | $0 (2021) |
| Medtronic Vascular, Inc. | $344.52 | 11 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $251.06 | 15 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.92 | 1 | Novartis Pharmaceuticals Corporation ($17.92) |
| 2023 | $13.66 | 1 | Novartis Pharmaceuticals Corporation ($13.66) |
| 2021 | $1,020 | 59 | Amarin Pharma Inc. ($183.54) |
| 2020 | $1,218 | 61 | Amarin Pharma Inc. ($252.48) |
| 2019 | $1,461 | 85 | Amgen Inc. ($220.29) |
| 2018 | $1,716 | 107 | Gilead Sciences, Inc. ($236.81) |
| 2017 | $1,929 | 117 | Gilead Sciences Inc ($327.56) |
All Payment Transactions
431 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/30/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/24/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/23/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/13/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/11/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.71 | General |
| Category: Cardiovascular | ||||||
| 08/09/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Cardiology | ||||||
| 08/03/2021 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Cardiovascular | ||||||
| 07/21/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.91 | General |
| Category: Cardiovascular | ||||||
| 07/19/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/16/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/14/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/13/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/12/2021 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Cardiovascular | ||||||
| 06/29/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: DIABETES | ||||||
| 06/25/2021 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/22/2021 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: Genetic Disease | ||||||
| 06/21/2021 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/18/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/15/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/10/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/08/2021 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Cardiovascular | ||||||
| 06/08/2021 | PFIZER INC. | VYNDAQEL (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/07/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 23 | 3,217 | 4,032 | $753,231 | $295,840 |
| 2020 | 25 | 4,404 | 6,274 | $1.1M | $420,713 |
Total Patients
7,621
Total Services
10,306
Medicare Billing
$716,553
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 169 | 169 | $202,800 | $65,308 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 587 | 657 | $119,574 | $53,928 | 45.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 152 | 191 | $38,582 | $25,184 | 65.3% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 162 | 163 | $88,975 | $25,004 | 28.1% |
| 93880 | Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck | Office | 2021 | 150 | 152 | $63,840 | $21,970 | 34.4% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 105 | 420 | $25,200 | $19,109 | 75.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 83 | 85 | $20,570 | $13,512 | 65.7% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 775 | 943 | $40,549 | $9,920 | 24.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 63 | 63 | $15,876 | $9,559 | 60.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 74 | 164 | $23,288 | $9,394 | 40.3% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2021 | 167 | 169 | $12,760 | $8,485 | 66.5% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2021 | 169 | 169 | $34,307 | $7,790 | 22.7% |
| 93229 | Heart rhythm tracing, computer analysis, physician prescribed transmission of patient-triggered events greater than 24-hour ekg up to 30 days | Office | 2021 | 13 | 13 | $12,350 | $7,139 | 57.8% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 92 | 93 | $17,110 | $5,198 | 30.4% |
| 93224 | Heart rhythm tracing, analysis, and interpretation of 48-hour ekg, includes recording, scanning analysis with report | Office | 2021 | 53 | 54 | $13,554 | $3,043 | 22.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 28 | 32 | $5,376 | $2,615 | 48.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 45 | $5,085 | $2,186 | 43.0% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 226 | 283 | $5,660 | $1,906 | 33.7% |
| 93280 | Evaluation, testing, and programming adjustment of permanent dual lead pacemaker system with physician analysis, review, and report | Office | 2021 | 18 | 22 | $1,936 | $1,436 | 74.2% |
| 93294 | Remote evaluations of single, dual, or multiple lead pacemaker system with qualified health care professional analysis, review, and report, up to 90 days | Office | 2021 | 21 | 46 | $1,932 | $1,021 | 52.8% |
| 93296 | Remote evaluations of single, dual, or multiple lead pacemaker system or implantable defibrillator system with technician review, support and distribution of results, up to 90 days | Office | 2021 | 24 | 52 | $1,716 | $978.53 | 57.0% |
| 93288 | Evaluation of parameters of leadless, single, dual, or multiple lead pacemaker system with qualified health care professional analysis, review, and report | Office | 2021 | 14 | 20 | $1,420 | $831.90 | 58.6% |
| 93228 | Heart rhythm tracing, computer analysis, and interpretation of patient-triggered events greater than 24-hour ekg up to 30 days | Office | 2021 | 13 | 13 | $650.00 | $256.44 | 39.5% |
| 93005 | Routine electrocardiogram (ekg) with tracing using at least 12 leads | Office | 2021 | 14 | 14 | $120.72 | $65.92 | 54.6% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2020 | 222 | 222 | $266,400 | $86,995 | 32.7% |
About Dr. Chen Tung, MD
Dr. Chen Tung, MD is a Cardiovascular Disease healthcare provider based in Frederick, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1588667976.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chen Tung, MD has received a total of $7,376 in payments from pharmaceutical and medical device companies, with $17.92 received in 2024. These payments were reported across 431 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($7,346).
As a Medicare-enrolled provider, Tung has provided services to 7,621 Medicare beneficiaries, totaling 10,306 services with total Medicare billing of $716,553. Data is available for 2 years (2020–2021), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Frederick, MD
- Active Since 05/31/2005
- Last Updated 03/31/2015
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1588667976
Products in Payments
- XARELTO (Drug) $699.26
- ENTRESTO (Drug) $671.73
- Vascepa (Drug) $577.59
- Corlanor (Drug) $432.32
- PRALUENT (Drug) $418.12
- BRILINTA (Drug) $404.47
- Ranexa (Drug) $277.44
- NEXLETOL (Drug) $244.90
- Repatha (Biological) $233.79
- Confirm Rx (Device) $193.86
- ELIQUIS (Drug) $189.34
- JARDIANCE (Drug) $155.32
- WATCHMAN (Device) $150.35
- Edarbi (Drug) $150.29
- Resolute (Device) $141.44
- MRI Ready Leads (Device) $127.62
- PRALUENT ALIROCUMAB INJECTION (Biological) $125.37
- Savaysa (Drug) $98.05
- PRADAXA (Drug) $95.74
- LifeVest (Device) $86.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Frederick
Dr. Stephen Williams, M.d., M.p.h, M.D., M.P.H
Cardiovascular Disease — Payments: $71,640
Cardiovascular Disease $71,640
Kusay Barakat, M.d, M.D
Cardiovascular Disease — Payments: $19,947
Cardiovascular Disease $19,947
Shawn Buki, Md, MD
Cardiovascular Disease — Payments: $5,874
Cardiovascular Disease $5,874
Dr. Samir Ahuja, M.d, M.D
Cardiovascular Disease — Payments: $4,749
Cardiovascular Disease $4,749
Dr. John Vitarello, M.d, M.D
Cardiovascular Disease — Payments: $3,956
Cardiovascular Disease $3,956
David Yu, M.d, M.D
Cardiovascular Disease — Payments: $3,797
Cardiovascular Disease $3,797